Buscar
01/09/2025
Sex-related differences in the efficacy and toxicity of cancer treatments
Bertrán, AS, Rodríguez, JAM, Cardeña-Gutiérrez, A, Martinez-Callejo, V, Higuera, O, Bernardez, B, Moreno-Martínez, ME, Majem, M. Sex-related differences in the efficacy and toxicity of cancer treatments. Clinical & Translational Oncology. 2025; 27(9)DOI:10.1007/s12094-025-03893-2. PMID:40153220. IF:2.500(Q3/6D).
26/08/2025
Opening of a phase Ib/II study to investigate the safety and efficacy of Afatinib in patients with Fanconi anemia and unresectable locally advanced or metastatic head and neck squamous cell carcinoma
Anguera, G, Gallego, O, Llobet, M, Berga, N, Moreno-Martinez, ME, Leon, X, Kratz, C, Garcia-Escudero, R, Minguillón, J, Surrallés, J. Opening of a phase Ib/II study to investigate the safety and efficacy of Afatinib in patients with Fanconi anemia and unresectable locally advanced or metastatic head and neck squamous cell carcinoma. BMC CANCER. 2025; 25(1)DOI:10.1186/s12885-025-14619-6. PMID:40859225. IF:3.400(Q2/4D).
18/08/2025
Integrating Global Surveillance, Local Action, and Innovative Stewardship Against Antimicrobial Resistance
Ruiz-Ramos, J. Integrating Global Surveillance, Local Action, and Innovative Stewardship Against Antimicrobial Resistance. Antibiotics-Basel. 2025; 14(8)DOI:10.3390/antibiotics14080835. PMID:40868029. IF:4.600(Q1/2D).
08/08/2025
The Role of Pharmacogenetic Biomarkers in Pain
da Silva, IM, Plaza-Díaz, A, Ruiz-Ramos, J, Juanes-Borrego, A, Riera, P. The Role of Pharmacogenetic Biomarkers in Pain. Biomedicines. 2025; 13(8)DOI:10.3390/biomedicines13081935. PMID:40868188. IF:3.900(Q1/3D).
01/07/2025
Hemodynamic effects of carvedilol plus simvastatin in cirrhosis with severe portal hypertension and suboptimal response to ß-blockers: A double-blind, placebo-controlled, randomized trial
Alvarado-Tapias, E, Brujats, A, Puente, A, Ardevol, A, Rodriguez-Arias, A, Fajardo, J, Pavel, O, Garcia-Guix, M, Aracil, C, Poca, M, Cuyàs, B, Cantó, E, Montañés, R, Garcia-Osuna, A, Escorsell, A, Torras, X, Villanueva, C. Hemodynamic effects of carvedilol plus simvastatin in cirrhosis with severe portal hypertension and suboptimal response to ß-blockers: A double-blind, placebo-controlled, randomized trial. HEPATOLOGY. 2025; 82(1)DOI:10.1097/HEP.0000000000001148. PMID:39509369. IF:15.800(Q1/1D).
01/07/2025
Successful implementation of a bundle to prevent increased excessive-spectrum antimicrobial use under new EUCAST susceptibility definitions: a quasi-experimental study in a tertiary hospital
Duch-Llorach, P, Simonetti, AF, Figueras-Roig, A, Rivera, A, de Gamarra-Martínez, EF, Gras-Martin, L, Moreno-Martinez, ME, Ramos, JR, Zarate-Tamames, B, Navarro, F, López-Contreras, J, Escolà-Vergé, L. Successful implementation of a bundle to prevent increased excessive-spectrum antimicrobial use under new EUCAST susceptibility definitions: a quasi-experimental study in a tertiary hospital. JOURNAL OF HOSPITAL INFECTION. 2025; 161DOI:10.1016/j.jhin.2025.04.016. PMID:40306370. IF:3.100(Q1/3D).
01/05/2025
Complementary and alternative medicine in HIV care: frequency of consumption, risks and interactions with antiretroviral therapy
Colominas-Gonzalez, E, De Antonio, M, Masip, M, Conde, MTM, Cardona, G, Restituto, DF, Comas, D, Roch, MA, Lopez, B, Torres-Bondia, FI, Retamero, A, Knobel, H, Luque, S. Complementary and alternative medicine in HIV care: frequency of consumption, risks and interactions with antiretroviral therapy. EUROPEAN JOURNAL OF HOSPITAL PHARMACY. 2025; 32(3)DOI:10.1136/ejhpharm-2024-004118. PMID:38802166. IF:1.500(Q4/8D).
17/04/2025
HSP-CAR30 with a high proportion of less-differentiated T cells promotes durable responses in refractory CD30+lymphoma
Caballero, AC, Ujaldón-Miró, C, Pujol-Fernández, P, Montserrat-Torres, R, Guardiola-Perello, M, Escudero-López, E, Garcia-Cadenas, I, Esquirol, A, Martino, R, Jara-Bustamante, P, Ezquerra, P, Soria, JM, Iranzo, E, Moreno-Martinez, ME, Riba, M, Sierra, J, Alvarez-Fernández, C, Escribà-Garcia, L, Briones, J. HSP-CAR30 with a high proportion of less-differentiated T cells promotes durable responses in refractory CD30+lymphoma. BLOOD. 2025; 145(16)DOI:10.1182/blood.2024026758. PMID:39841453. IF:23.100(Q1/1D).